Weight change with atypical antipsychotics in the treatment of schizophrenia (Q36310286)

13 August 2017

1 reference

title

Weight change with atypical antipsychotics in the treatment of schizophrenia (English)

1 reference

13 August 2017

0 references

Peter Haddad

1

1 reference

PubMed ID

16280334

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Journal of Psychopharmacology

13 August 2017

1 reference

13 August 2017

19

1 reference

13 August 2017

6 Suppl

1 reference

13 August 2017

16-27

1 reference

The impact of weight gain on quality of life among persons with schizophrenia.

13 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Weight changes during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Differential effect of clozapine on weight: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Quetiapine : A Review of its Use in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105058378

21 January 2018

Identifiers

DOI

10.1177/0269881105058378

1 reference

13 August 2017

1 reference

PubMed ID

16280334